We have demonstrated the generalizability of the MYC-mRNA drug’s therapeutic efficacy across different pancreatic cancer models of PSN1, MIA-Paca-2, and PANC1 and validated its inhibition of the high c-MYC-expressing PSN1 in vivo with significant survival outcome. The gene discussed is NT5C3A; the disease is familial pancreatic carcinoma.